Literature DB >> 22564868

The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Abby R Rosenberg1, Stephen X Skapek, Douglas S Hawkins.   

Abstract

"Convenience cohorts" comprise individuals thought to represent the general population, but chosen because they are readily available for evaluation, rather than at random. As such, these methods are subject to bias and may be misleading. Convenience cohorts have been used to investigate the prognostic significance of chromosomal translocations between the PAX3 or PAX7 and the FOXO1 genes in rhabdomyosarcoma, the most common pediatric sarcoma. However, retrospective studies assessing the role of PAX-FOXO1 translocations have yielded inconsistent results. This review highlights the findings from several clinical correlation studies of the PAX-FOXO1 biomarker and illustrates the challenges of using such methods to draw clinical conclusions. ©2012 AACR

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22564868      PMCID： PMC3392538          DOI： 10.1158/1055-9965.EPI-12-0207

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


  24 in total

1.  Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma.

Authors:  J A Biegel; R S Meek; A H Parmiter; K Conard; B S Emanuel
Journal:  Genes Chromosomes Cancer       Date:  1991-11       Impact factor: 5.006

Review 2.  Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Authors:  R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist
Journal:  J Pediatr Hematol Oncol       Date:  2001-05       Impact factor: 1.289

3.  Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.

Authors:  K S Baker; J R Anderson; M P Link; H E Grier; S J Qualman; H M Maurer; J C Breneman; E S Wiener; W M Crist
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

5.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Authors:  Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

6.  PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.

Authors:  Sarah N Dumont; Alexander J Lazar; Julia A Bridge; Robert S Benjamin; Jonathan C Trent
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-17       Impact factor: 4.553

Review 7.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.

Authors:  F G Barr
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

8.  Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma.

Authors:  E C Douglass; S T Rowe; M Valentine; D M Parham; R Berkow; W P Bowman; H M Maurer
Journal:  Genes Chromosomes Cancer       Date:  1991-11       Impact factor: 5.006

9.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.

Authors:  John C Breneman; Elizabeth Lyden; Alberto S Pappo; Michael P Link; James R Anderson; David M Parham; Stephen J Qualman; Moody D Wharam; Sarah S Donaldson; Harold M Maurer; William H Meyer; K Scott Baker; Charles N Paidas; William M Crist
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

10.  Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?

Authors:  J Anderson; T Gordon; A McManus; T Mapp; S Gould; A Kelsey; H McDowell; R Pinkerton; J Shipley; K Pritchard-Jones
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640
View more
  15 in total

1.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

2.  Inconvenience of convenience cohorts--letter.

Authors:  Daniel Williamson; Edoardo Missiaglia; Julia Chisholm; Janet Shipley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

3.  Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Authors:  Tobias M Dantonello; Christian Vokuhl; Monika Scheer; Monika Sparber-Sauer; Sabine Stegmaier; Guido Seitz; Heike Scheithauer; Jörg Faber; Iris Veit-Friedrich; Peter Kaatsch; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Virchows Arch       Date:  2018-02-21       Impact factor: 4.064

4.  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Erin R Rudzinski; James R Anderson; Yueh-Yun Chi; Julie M Gastier-Foster; Caroline Astbury; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; Brenda J Weigel; Alberto Pappo; William H Meyer; Michael A Arnold; Lisa A Teot; David M Parham
Journal:  Pediatr Blood Cancer       Date:  2017-05-18       Impact factor: 3.167

Review 5.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

6.  PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.

Authors:  Stephen X Skapek; James Anderson; Frederic G Barr; Julia A Bridge; Julie M Gastier-Foster; David M Parham; Erin R Rudzinski; Timothy Triche; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2013-03-22       Impact factor: 3.167

7.  Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group.

Authors:  Theodore W Laetsch; Angshumoy Roy; Lin Xu; Jennifer O Black; Cheryl M Coffin; Yueh-Yun Chi; Jing Tian; Sheri L Spunt; Douglas S Hawkins; Julia A Bridge; D Williams Parsons; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2018-04-24       Impact factor: 12.531

8.  A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma.

Authors:  Leo Mascarenhas
Journal:  J Clin Oncol       Date:  2021-06-28       Impact factor: 50.717

9.  Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients.

Authors:  Sarah N Dumont; Dejka M Araujo; Mark F Munsell; Jason A Salganick; Amaury G Dumont; Kevin A Raymond; Claude Linassier; Shreyaskumar Patel; Robert S Benjamin; Jonathan C Trent
Journal:  Cancer Med       Date:  2013-07-15       Impact factor: 4.452

Review 10.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Authors:  Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.